Marijuana Inc (PK) (MAJI) News

These guys didn't waste any time lying to shareholders. Lol.

You can't even sell this turd. Where is the MJ company? Where is the news? Where r the filings and PRs that were promised in October? All BS as usual.

What material changes can we expect to support this position? There seems to be very little interest.

The last M is magic? JC, run!

$MAJI Shareholders | We’re thrilled to share the launch of our new Youtube channel for our company that’s determined to make a difference in the fight against cancer. In our latest video, our CEO Mike Sheikh outlines some of the exciting work we’ve begun - Stay Tuned!

https://x.com/Exousia_Pro/status/1888962633497227467

dead?

GRNF all over again.

ExousiaPro-Investor-Presentation-Deck

https://exousiapro.com/wp-content/uploads/2025/02/ExousiaPro-Investor-Presntation-Deck-1-31-25.pdf

MAJI

a 3 to 5 million float eom

Is there any reason to see upside here anymore? waiting for signatures and approvals in OTC is usually more exciting than when it happens.... bc it never does.

LOL, another JC i guess. Ghost town again.

$MAJI - The transfer agent has made the reduction and reduced the A/S to 250,000,000! OTC should reflect this during its next update

https://x.com/Exousia_Pro/status/1882880771201151191

As the pps erodes with no updates. Back to .01

More sells than buys

Wow, just got back home, what happened to the sp?

$MAJI Lots of follow up ongoing from the #JPM25 conference in terms of licensing partners. Key connections made with a number of big pharma’s. Accomplished 2 presentations to Healthcare investment bankers at the conference. The feedback was positive. Expect to release slide deck before
@golly Feb 25

https://x.com/Exousia_Pro/status/1882519568993923573

Volume is very light right now across almost all of the small/micro cap OTCs. .... and MAJI is still super undiscovered.

I believe we will see our .10-.25 breakout with 1-2 weeks

The CEO has been great to chat with -- there's a lot to be excited about in the very near term.

You can contact him if you need any reassurances on where the company is going

$MAJI

MAJI

Somebody needs to tell MAJI the market is open. Holidays are over, let's go. Volume needed.

Good morning $MAJI Shareholders || Our CEO, Mike Sheikh, is in San Francisco at the J.P. Morgan 43rd Annual Healthcare Conference 2025 representing ExousioPRO! Very exciting time as he will be networking & conducting presentations about our #exosome #oncology treatment. More to come after Mike gets back.

https://x.com/Exousia_Pro/status/1878797586095554973

MAJI

Actually a really nice development. Management showing they mean business and care about not diluting.

So many dilution machine pieces of shit on the OTC, refreshing to see that’s not the case here.

Wont be long til we are .10 - .20 range IMO

$MAJI

MAJI

47 mil common shares now cancelled, being replaced by preferred shares

Good Morning $MAJI Shareholders | Excited to announce this corporate update, to further highlight management's commitment to shareholder value as we enter the company's growth phase. More to come shortly, stay tuned!

https://x.com/Exousia_Pro/status/1877718081155297443

MAJI

I didn't need to do homework to know what was coming. A big fat joke as usual in the otc. Fake advisors, fake profiles, all scams nearly.

Do some homework. New CEO was with BIXT. BIXT is a joke run by David Platt who ran one healthcare company into the ground and who has been telling the same BS science story for well over 10 years New CEO claims to have worked for Dean Witter and National. There is no such person I can find on the FINRA site who was registered under that name. 

Less interest in the stock now than before the news came out yesterday. Lol. 0 volume so far.

$MAJI Shareholders | Exousia is in talks to license several other patents using Exosomes, which, once secured, will allow the company to expand its oncology studies beyond GBM. More to come on this later. #Glioblastoma #Cancer

https://x.com/Exousia_Pro/status/1876630249879801900

MAJI

$MAJI Shareholders | To show that shareholder value is priority #1 for us, the issued shares will be restricted for 21 months. Assuming 15 months for an uplist followed by a lockup agreement for another 6 months.

https://x.com/Exousia_Pro/status/1876304421573005660

MAJI

Marijuana, Inc., Completes Acquisition of Exousia AI and Enters Expanding Exosome Market

ST. PETERSBURG, Fla., Jan. 6, 2025 /PRNewswire/ -- Marijuana, Inc. (OTCPINK: MAJI), dba Exousia Pro, Inc., has acquired 100% of Exousia AI in a cash and stock transaction from Ludwig Enterprises, Inc. Exousia Pro will issue 47,000,000 million restricted shares of its Common stock to Ludwig Enterprises.
The 47,000,000 shares being issued are restricted shares with certain lock-up features. The legend cannot be removed until six months AFTER Exousia Pro has completed its up-listing with NASDAQ or an equivalent exchange. The Company further agreed to assume liabilities under $75,000 and issued Ludwig a Note for $100,000.
Exousia AI is a leading USA-based biotechnology company in the field of Exosomes. The Company secured a worldwide license for its Exosome technology. The technology covers growing and extracting plant-based exosomes and loading them for use as a drug delivery system. The loading process can also be applied to human-derived exosomes. The acquisition includes an ongoing study on using Exosomes to treat Glioblastoma ("GBM"). The study is well underway, with very promising initial findings. Exousia AI is involved in other studies, including one study concluding in Italy. Exousia Pro will enter two additional studies covering dermatology and the dental market that are part of the acquisition.
Exousia Pro will manufacture and sell vials of wet exosomes or jars of dried exosomes to the nutraceutical and dermatology markets. The OTC exosome market, known as cosmeceuticals, is rapidly expanding due to consumer demand for antiaging and regenerative skincare solutions. A 30-day treatment for skin and hair sells for $400 a vial. Reports suggest a compound annual growth rate of 10%, growing from $310 million in 2025 to $633 million in 2033, for the exosomes skincare market; this is a global trend, with markets in North America, Europe, and Asia Pacific showing strong growth.
Exousia is in talks to license several other patents using Exosomes, which, once secured, will allow the Company to expand its oncology studies beyond GBM.
When Exousia Pro proves its technology enhances current chemotherapy drugs on the market, it can contact the drug manufacturers and license the tech for use in their drug therapy.
"The exosome market is in its infancy, but poised for explosive growth, as evidence by a surge of promising studies," said CEO of Marijuana Inc., Michael Sheikh. "Mounting research points to the vast therapeutic potential of exosomes, highlighting their capacity to precisely target diseases while minimizing side effects. Investors may not fully appreciate the dominance of monoclonal antibodies, which now lead the pharmaceutical market in revenue. This success stems from their ability to target diseased cells, often delivering therapeutic payloads directly where needed. Every major pharmaceutical company is actively developing monoclonal antibody drugs, driven by the universal desire for treatments that alleviate symptoms without causing new ones."
"Exosomes represent the next generation of targeted therapies, surpassing monoclonal antibodies in several key aspects. They offer significant cost advantages in production, the capacity to deliver larger and more complex payloads, including sensitive molecules like DNA, and a broader range of applications. Importantly, exosomes also mitigate the risk of off-target effects and immune reactions often associated with current monoclonal antibody treatments. This would be a key selling point in the event of licensing discussions. Exosomes embody an elegant evolution in biotechnology, and Exousia Pro is committed to spearheading their commercialization and therapeutic development."


https://finance.yahoo.com/news/marijuana-inc-completes-acquisition-exousia-140000497.html

Stay tuned

https://x.com/Exousia_Pro/status/1874473749602525682

Yes, would like to see some insider buys to start the new year.

MAJI

Start of January 2025 is planned news for $MAJI . Expecting we start to breakout here

.07+ coming quick imo

MAJI

We plan to start 2025 with a bang, so please keep checking back and stay tuned!

https://x.com/Exousia_Pro/status/1871557741468361057

MAJI

Exousia Pro filed the Amendment for our Articles to reduce the Authorized shares from 750 million to 250 million today. The filing should be visible on http://sunbiz.org by January 2, 2025.

https://x.com/OTC_GRNF/status/1870175401370140808

$MAJI

Just a pathetic bash attempt. It’s a good sign he showed up though, thats how you know this is about to take off.

Classic

$MAJI

MAJI

Well, seems like a narrow vision to take, but it's really too soon to know. I hope you are wrong.

Nice Corporate update; opposed to toxic debt,15 mo. plan to uplist to NASDQ,

https://x.com/OTC_GRNF/status/1869389298807845282

It is impossible to remove Costello’s stench from anything he was associated with. Just ask Rose or whatever his wife’s name is. Ask his baby momma

Costello scam just by another name in my opinion

Totally new ticker, new management, new everything. People already bashing it, lol. Maybe instead of being negative about it, we can get a little redemption for those who got scammed by Costello. However, grnf did pump to over $2 for a minute and many made bank on that scam. Perhaps we'll see $2 here one day.

LOL

Your'e probably right........

Still a Justin Costello SCAM. It’s tainted forever from Costello

I know that.

Why wouldn't they change it on their twitter feed?

eom

Previous ticker eom

Why does it say GRNF?

$MAJI filed OTC Quarterly Disclosures today. Transparency is one of our top priorities.

https://x.com/OTC_GRNF/status/1868787614628909301

https://www.otcmarkets.com/stock/MAJI/disclosure

MAJI: Ushering In A New Era With Transformative Biotech Acquisition

A significant transformation is underway for the OTC PINK listed $MAJI. The company is executing a high-profile acquisition of Exousia Pro, Inc. (EXO), a biotech venture at the forefront of next-generation medicine. With a new direction rooted in cutting-edge biotech, an imminent name change, and this transformative acquisition, MAJI is positioning itself to deliver what could be a breakthrough in modern healthcare.
At the heart of this transformation is EXO’s exclusive worldwide rights to patent-pending technology that utilizes exosomes – tiny, natural nanoparticles capable of delivering genetic material directly to diseased cells and tissues. This innovative platform, which harnesses both mammalian and plant-based exosomes, has the potential to address some of today’s most challenging health conditions, including cancer and cardiovascular diseases.
Why is this technology generating so much attention from researchers and clinicians? Exosomes act as the body’s natural delivery system, transporting genetic instructions and molecular cargo between cells. EXO’s proprietary advancements take this one step further by engineering exosomes to “carry” therapeutic molecules – such as DNA or mRNA – and deliver them precisely to their targets. By reducing off-target effects and improving delivery efficiency, this technology promises a level of precision that traditional treatments often lack.
This potential is grounded in the collaboration that brought it to life. EXO is a joint venture of Progenicyte Japan, a biotechnology firm renowned for its work in genetic engineering, regenerative medicine, and advanced drug delivery systems. Progenicyte Japan’s collaborations with the University of Florida and Kyoto University bring world-class academic expertise and intellectual resources to EXO’s mission. Together, they are pushing the boundaries of what exosome technology can achieve – not just in oncology, but also in areas such as Alzheimer’s disease and Down syndrome.
Marijuana Inc

The acquisition is further bolstered by the company’s efforts to set the stage for success in its new era. Plans to pursue SEC reporting status and adopt a leaner share structure – from 750 million authorized shares down to 250 million – demonstrate a commitment to transparency and a more shareholder-friendly framework. Updates on the OTC Markets platform are already in progress, and the company has announced plans for a name change and a new website launch set for January 1, 2025.
This transformation is unfolding at a time when the healthcare industry is eager for breakthrough solutions. Many existing treatments struggle to deliver therapeutic agents precisely where they are needed, leading to limited efficacy and unwanted side effects. EXO’s exosome-based approach offers a highly tailored solution, potentially overcoming these challenges. For example, the company has indicated interest in glioblastoma, a particularly aggressive form of brain cancer, where targeted therapies could offer new hope for patients.
With its new brand set to launch on January 1, 2025, MAJI is ready to step into the biotech space with purpose. The acquisition of EXO brings advanced exosome technology to the forefront, positioning the company to address some of medicine’s toughest challenges, including cancer, Alzheimer’s, and glioblastoma. This launch represents a key moment in MAJI’s transformation and potentially a major step forward for modern healthcare.
*This article has been cross-published from DegenMag.com; See all disclosures and disclaimers here

https://x.com/DegenMagazine/status/1868558821729149089

Now they are reducing the AS by 67%


750M AS to 250M AS

Another good measure of progress

MAJI

$MAJI

Company tweet:
https://x.com/OTC_GRNF/status/1866909237009326369

That’s roughly what I’m targeting as well.

10 mil MC, which is reasonable for a small bio company, would be ~.28/share. This may bring a much higher MC.

MAJI

The applications for this technology are insanely valuable.

Hold on tight, we’re in for a ride once the rest of the OTC finds us

$MAJI

MAJI

Great job, great DD eom

Nice DD, looks like it is Exousia and Progenicyte!